Vaccines Never Prevented the Transmission of COVID
https://www.tabletmag.com/sections/science/articles/vaccines-never-prevented-transmission-covid-alex-gutentag
January 23, 2023
Bill Gates Admits COVID Vaccines Don’t Work
https://www.newswars.com/must-watch-bill-gates-admits-covid-vaccines-dont-work/ – discussion at the Lowy Institute in Sydney, Australia
He said: “We also need to fix the three problems of [mRNA] vaccines. The current vaccines are not infection blocking. They’re not broad, so when new variants come up you lose protection, and they have very short duration, particularly in the people who matter, which are old people.”
January 13, 2023
New York State Supreme Court Judge Gerard Neri ruled that Governor Kathy Hochul and the state’s health department overstepped their authority by sidestepping the Legislature and issuing an executive order requiring vaccines for health care workers. Judge Neri said the state is prohibited from mandating vaccinations outside of what is detailed in public health law, which included mentions of mumps, measles and hepatitis. He said the state acknowledges vaccines don’t prevent COVID transmission. (The judge also said the state acknowledges vaccines don’t prevent covid transmission despite the title of the executive order: “Prevention of COVID-19 transmission by covered entities”)
https://www.msn.com/en-us/health/other/syracuse-judge-strikes-down-ny-vaccine-mandate-for-health-workers-rules-state-overstepped-its-authority/ar-AA16lmi4
October 2022
Pfizer Exec Admits COVID Vaccine Was Not Tested for Preventing Transmission
A Pfizer executive said Monday that neither she nor other Pfizer officials knew whether its COVID-19 vaccine would stop transmission before entering the market last year.
Member of the European Parliament, Rob Roos, asked during a session: https://www.youtube.com/shorts/-CCaJLR1zhQ
“Was the Pfizer COVID vaccine tested on stopping the transmission of the virus before it entered the market? Did we know about stopping immunization before it entered the market?”
Pfizer’s Janine Small, president of international developed markets, said in response:
“No … You know, we had to … really move at the speed of science to know what is taking place in the market.”
Roos, of the Netherlands, argued in a Twitter video Monday that following Small’s comments to him, millions of people around the world were duped by pharmaceutical companies and governments.
“Millions of people worldwide felt forced to get vaccinated because of the myth that ‘you do it for others,’” Roos said. “Now, this turned out to be a cheap lie” and “should be exposed,” he added.
July 22, 2022
Dr. Deborah Birx, MD, former head of the White House COVID-19 Task Force said in a television interview that she always knew the “vaccine” would not work to stop infection, but publicly for the year leading up to July 2022, she said publicly that the vaccines would indeed stop infection and transmission.
August 6, 2021
Dr. Rochelle Walensky (CDC Director)
“Our vaccines are working exceptionally well,” Dr. Rochelle Walensky (CDC Director) told CNN’s Wolf Blitzer. “…what they can’t do anymore is prevent transmission.”
January 4, 2021
Trials are not designed to assess whether the vaccines can interrupt viral transmission.
December 10, 2020
FDA: “Data are limited to assess the effect of the vaccine against transmission of SARS-CoV-2 from individuals who are infected despite vaccination. Demonstrated high efficacy against symptomatic COVID-19 may translate to overall prevention of transmission in populations with high enough vaccine uptake, though it is possible that if efficacy against asymptomatic infection were lower than efficacy against symptomatic infection, asymptomatic cases in combination with reduced mask-wearing and social distancing could result in significant continued transmission. Additional evaluations including data from clinical trials and from vaccine use post-authorization will be needed to assess the effect of the vaccine in preventing virus shedding and transmission, in particular in individuals with asymptomatic infection.”
https://www.fda.gov/media/144245/download
October 21, 2020
Will covid-19 vaccines save lives? Current trials aren’t designed to tell us
https://www.bmj.com/content/371/bmj.m4037
As phase III trials of covid-19 vaccines reach their target enrollments, officials have been trying to project calm. The US coronavirus czar Anthony Fauci and the Food and Drug Administration leadership have offered public assurances that established procedures will be followed.1234 Only a “safe and effective” vaccine will be approved, they say, and nine vaccine manufacturers issued a rare joint statement pledging not to prematurely seek regulatory review.5
But what will it mean exactly when a vaccine is declared “effective”? To the public this seems fairly obvious. “The primary goal of a covid-19 vaccine is to keep people from getting very sick and dying,” a National Public Radio broadcast said bluntly.6
Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, “Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission.”7
Yet the current phase III trials are not actually set up to prove either (table 1). None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.
Evaluating mild, not severe, disease
In a September interview Medscape editor in chief Eric Topol pondered what counts as a recorded “event” in the vaccine trials. “We’re not talking about just a PCR [polymerase chain reaction test]-positive mild infection. It has to be moderate to severe illness to qualify as an event, correct?” he asked.8
“That’s right,” concurred his guest, Paul Offit, a vaccinologist who sits on the FDA advisory committee that may ultimately recommend the vaccines for license or emergency use authorization.
But that’s not right. In all the ongoing phase III trials for which details have been released, laboratory confirmed infections even with only mild symptoms qualify as meeting the primary endpoint definition.9101112 In Pfizer and Moderna’s trials, for example, people with only a cough and positive laboratory test would bring those trials one event closer to their completion. (If AstraZeneca’s ongoing UK trial is designed similarly to its “paused” US trial for which the company has released details, a cough and fever with positive PCR test would suffice.)
Part of the reason may be numbers. Severe illness requiring hospital admission, which happens in only a small fraction of symptomatic covid-19 cases, would be unlikely to occur in significant numbers in trials. Data published by the US Centers for Disease Control and Prevention in late April reported a symptomatic case hospitalization ratio of 3.4% overall, varying from 1.7% in 0-49 year olds and 4.5% in 50-64 year olds to 7.4% in those 65 and over.13 Because most people with symptomatic covid-19 experience only mild symptoms,14 even trials involving 30 000 or more patients would turn up relatively few cases of severe disease.
In the trials, final efficacy analyses are planned after just 150 to 160 “events,”—that is, a positive indication of symptomatic covid-19, regardless of severity of the illness.
Yet until vaccine manufacturers began to release their study protocols in mid-September, trial registries and other publicly released information did little to dispel the notion that it was severe covid-19 that the trials were assessing. Moderna, for example, called hospital admissions a “key secondary endpoint” in statements to the media.15 And a press release from the US National Institutes of Health reinforced this impression, stating that Moderna’s trial “aims to study whether the vaccine can prevent severe covid-19” and “seeks to answer if the vaccine can prevent death caused by covid-19.”16
But Tal Zaks, chief medical officer at Moderna, told The BMJ that the company’s trial lacks adequate statistical power to assess those outcomes. “The trial is precluded from judging [hospital admissions], based on what is a reasonable size and duration to serve the public good here,” he said.
Hospital admissions and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30 000 people. The same is true of its ability to save lives or prevent transmission: the trials are not designed to find out.
Zaks said, “Would I like to know that this prevents mortality? Sure, because I believe it does. I just don’t think it’s feasible within the timeframe [of the trial]—too many would die waiting for the results before we ever knew that.”
Stopping transmission
What about Hotez’s second criterion, interrupting virus transmission, which some experts have argued17 should be the most important test in phase III studies?
“Our trial will not demonstrate prevention of transmission,” Zaks said, “because in order to do that you have to swab people twice a week for very long periods, and that becomes operationally untenable.”
He repeatedly emphasized these “operational realities” of running a vaccine trial. “Every trial design, especially phase III, is always a balancing act between different needs,” he said. “If you wanted to have an answer on an endpoint that happens at a frequency of one 10th or one fifth the frequency of the primary endpoint, you would need a trial that is either 5 or 10 times larger or you’d need a trial that is 5 or 10 times longer to collect those events. Neither of these, I think, are acceptable in the current public need for knowing expeditiously that a vaccine works.”
Zaks added, “A 30 000 [participant] trial is already a fairly large trial. If you’re asking for a 300 000 trial then you need to talk to the people who are paying for it, because now you’re talking about not a $500m to $1B trial, you’re talking about something 10 times the size. And I think the public purse and operational capabilities and capacities we have are rightly spent not betting the farm on one vaccine but, as Operation Warp Speed [the US government’s covid-19 vaccine plan] is trying to do, making sure that we’re funding several vaccines in parallel.”
Our officials lied about ‘Not going to get COVID’ or even transmit, if vaccinated
A number of officials in the United States and around the world had claimed COVID-19 vaccines could prevent transmission. Among them,
- President Joe Biden in July 2021 remarked that “you’re not going to get COVID if you have these vaccinations.”
- Chief Biden administration medical adviser Dr. Anthony Fauci in May 2021 said in a CBS interview that vaccinated people are “dead ends” for COVID-19, suggesting they cannot transmit the virus. “When you get vaccinated, you not only protect your own health and that of the family but also you contribute to the community health by preventing the spread of the virus throughout the community,” Fauci said.
- Two months later, in late July of that year, Fauci said that vaccinated people are capable of transmitting the virus.
- In the coming months, Fauci, Biden, Centers for Disease Control and Prevention Director Dr. Rochelle Walensky and others pivoted to say the vaccine prevents severe disease, hospitalization and death from COVID-19.